Improving CD38 antibody therapy in multiple myeloma by enhancing effector cell-mediated killing mechanisms

被引：0
|
作者：
Eichholz, K. M. [1 ,2 ]
Roesner, T. [1 ,2 ]
Burger, R. [1 ,2 ]
Klausz, K. [1 ,2 ]
Otte, A. [1 ,2 ]
Valerius, T. [1 ,2 ]
Schewe, D. M. [2 ,3 ]
Gramatzki, M. [1 ,2 ]
Peipp, M. [1 ,2 ]
Kellner, C. [1 ,2 ]
机构：
[1] Christian Albrechts Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Christian Albrechts Univ Kiel, ALL BFM Study Grp, Pediat Hematol Oncol, Kiel, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V412
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [1] CELL-MEDIATED KILLING - EFFECTOR MECHANISMS AND MEDIATORS
    OJCIUS, DM
    YOUNG, JDE
    CANCER CELLS-A MONTHLY REVIEW, 1990, 2 (05): : 138 - 145
  • [2] Registering a CD38 antibody upfront for multiple myeloma
    Hofmeister, Craig C.
    Nooka, Ajay
    Kaufman, Jonathan L.
    Lonial, Sagar
    LANCET, 2019, 394 (10192): : 3 - 4
  • [3] CD38 Monoclonal Antibody Therapies for Multiple Myeloma
    Wong, Sandy W.
    Comenzo, Raymond L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 635 - 645
  • [4] Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors
    Song, Zhili
    Yang, Guang
    Wang, Anlai
    Greco, Rita
    Theilhaber, Joachim
    Shehu, Elvis
    Ajona, Daniel
    Paiva, Bruno
    Zhu, Chen
    Wiederschain, Dmitri
    Blondel, Marielle F. Chiron
    Adrian, Francisco
    CANCER RESEARCH, 2019, 79 (13)
  • [5] The Role of CD38 in Multiple Myeloma Cell Biology
    Kawano, Yawara
    Kushima, Saki
    Hata, Hiroyuki
    Matsuoka, Masao
    BLOOD, 2021, 138
  • [6] Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
    Lejeune, Margaux
    Duray, Elodie
    Peipp, Matthias
    Clemenceau, Beatrice
    Baron, Frederic
    Beguin, Yves
    Caers, Jo
    CANCERS, 2021, 13 (12)
  • [7] CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
    van de Donk, Niels W. C. J.
    Usmani, Saad Z.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [8] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
    de Weers, Michel
    Tai, Yu-Tzu
    van der Veer, Michael S.
    Bakker, Joost M.
    Vink, Tom
    Jacobs, Danielle C. H.
    Oomen, Lukas A.
    Peipp, Matthias
    Valerius, Thomas
    Slootstra, Jerry W.
    Mutis, Tuna
    Bleeker, Wim K.
    Anderson, Kenneth C.
    Lokhorst, Henk M.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    JOURNAL OF IMMUNOLOGY, 2011, 186 (03): : 1840 - 1848
  • [9] Resistance Mechanisms towards CD38-Directed Antibody Therapy in Multiple Myeloma
    Franssen, Laurens E.
    Stege, Claudia A. M.
    Zweegman, Sonja
    van de Donk, Niels W. C. J.
    Nijhof, Inger S.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [10] The multi-faceted potential of CD38 antibody targeting in multiple myeloma
    Shallis, Rory M.
    Terry, Christopher M.
    Lim, Seah H.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (06) : 697 - 703
12345